POS0106 BILAG-2004 LDA AND BST LDA ARE VALID TREAT TO TARGET IN SLE

Background: Low disease activity state has been defined using SLEDAI and used as treatment target in SLE. However, there not any such definition BILAG-2004 index (BILAG-2004). Objectives: This study was to determine if low according is valid for use We also assessed longitudinally systems tally (BST). BST an alternative way of representing scores that combines the flexibility simplification numerical scoring with clinical intuitiveness structure. Methods: a prospective multi-centre longitudinal UK inception cohort SLE patients (recruited within 12 months achieving 1997 ACR revised criteria SLE). Data were collected on (BILAG-2004 BILAG2004-Pregnancy Index during pregnancy), SLICC/ACR DI (SDI), cumulative drug exposure death at every visit. ran from 1st January 2005 31st December 2017. Four states (LDA) BILAG-2004: 1) LDA when all 9 had C, D or E assessment (no Grade A B), 2) persistent score between 2 consecutive visits (equivalent LDA), 3) Remission 4) Persistent visits. Longitudinal analysis Poisson regression random effects model development new damage outcome interest. Gender, cardiovascular risk factors, antiphospholipid syndrome status most drugs (except hydroxychloroquine, glucocorticoids, mycophenolate cyclophosphamide) excluded they associated univariate analysis. Results: 273 recruited (91.2% female, 59.3% Caucasian, 17.2% African/Caribbean, South Asian) mean age recruitment 38.5 years (SD 14.8). 97.8% no (2.2% SDI 1). Median follow-up 73.4 (range: 1.8, 153.8) total 1767 patient-years. There 13 deaths 114 items occurred follow-up. 6674 assessments score: 319 95 (84.6% only 1 system grade A, range: - 1704 B 239 (78.7% B, 5). achieved 74.5% (from 271 patients). 28.2% 234 6401 observations available (1 observation derived change assessments) 63.7% LDA. Table summarises multivariate which showed be inversely damage. Similar results obtained (RR 0.60 95% CI 0.38, 0.96) 0.65 0.43, 0.99). Cumulative since protective against 0.99 0.99, 1. Variable Relative Risk (95% CI) New Damage Ethnicity Afro-Caribbean 1.22 (0.68, 2.18) Asian 1.81 (0.97, 3.38) Others 2.22 (0.63, 7.85) Age diagnosis 1.06 (1.04, 1.08 ) Prior 0.68 (0.43, 1.06) (0.39, 0.94 Hydroxychloroquine last visit (per g (0.98, Steroids 100mg 1.02 (1.01, 1.03 Cyclophosphamide 1.67 (1.15, 2.41 Conclusion: are targets uncommon, make them unrealistic target. References: [1]Yee C. S., et al. The – novel longitudinally. Rheumatology (Oxford) 2012; 51[11]: 2099-2105. Acknowledgements : Versus Arthritis, Vifor Pharma Disclosure Interests: Chee-Seng Yee Consultant of: Bristol Myers Squibb, ImmuPharma, Grant/research support from: Pharma, Caroline Gordon Speakers bureau: UCB, Center Disease Control, Astra-Zeneca, MGP, Sanofi Mohammed Akil: None declared, Peter Lanyon: Christopher John Edwards Glaxo Smith Kline, Roche, David Isenberg: Anisur Rahman: Lee-Suan Teh: Sofia Tosounidou: Robert Stevens: Ahtiveer Prabu: Bridget Griffiths: Neil McHugh: Ian N. Bruce: Yasmeen Ahmad: Munther Khamashta: Vernon Farewell: declared